SPL028
Pharmaceutical compound
SPL028, or SPL-028, also known as α,α-dideutero-N,N-dimethyltryptamine (D2-DMT), is a psychedelic drug of the tryptamine family which is under development for the treatment of depressive disorders. It is the analogue of dimethyltryptamine (DMT) in which the α carbon has been dideuterated. SPL028's route of administration is intravenous injection or intramuscular injection.
01Pharmacology
SPL028 shows similar pharmacodynamics as DMT in vitro. Relatedly, SPL028 generalized with DMT in rodent drug discrimination tests. On the other hand, SPL028 differs from DMT in terms of pharmacokinetics; it is more resistant to metabolism and shows a prolonged duration. In a phase 1 clinical trial, SPL-028 by intramuscular injection produced robust psychedelic effects of short duration in humans.
02Research
SPL028 was originated by Small Pharma and is under development by Cybin. Small Pharma was acquired by Cybin in 2023. As of February 2024, SPL028 is in phase 1 clinical trials.
Sources and credits
This article is adapted from the Wikipedia article “SPL028”, written by its contributors and licensed under CC BY-SA 4.0. Fathomly has changed the layout, removed citation markers, navigation and maintenance notices, and adjusted punctuation. This adapted version is shared under the same license. For references, see the original article.
Images, from Wikimedia Commons:
- D2-DMT structure.svg by AlyInWikiWonderland, CC0
Fathomly is not affiliated with or endorsed by the Wikimedia Foundation. Spotted a problem? Tell us.
